Chief Financial Officer · Arcus Biosciences, Inc. · Common Stock
Side
A
Value
—
Shares
24.0K
Price
—
Executed
Jan 23, 2026
Disclosed
Jan 26, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 23 executedJan 26, 2026 disclosed
RCUS · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 35.3% of prior position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Goeltz II Robert C. filed this Form 4 reporting a grant or award of RCUS on Jan 23, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Goeltz II Robert C.cik:0001653881
Issuer
Arcus Biosciences, Inc.cik:0001724521
Revision history · 0
No field has changed since this record was first ingested.
